Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI)

K. Marschall, U. Munzel, M. Wedel, B. Fyrnys (Frankfurt, Germany)

Source: Annual Congress 2004 - Improvements in delivery of inhaled agents
Session: Improvements in delivery of inhaled agents
Session type: Thematic Poster Session
Number: 3576
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Marschall, U. Munzel, M. Wedel, B. Fyrnys (Frankfurt, Germany). Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI). Eur Respir J 2004; 24: Suppl. 48, 3576

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 472s
Year: 2003

Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020


In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019


Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs)
Source: Eur Respir J 2006; 28: Suppl. 50, 614s
Year: 2006

Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Inhalers and their use
Year: 2017


Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005